TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

Abbott Launches Pivotal Trial of TriClip Tricuspid Valve Repair System
News | Heart Valve Technology | September 05, 2019

September 5, 2019 — Abbott announced the launch of the company's TRILUMINATE Pivotal trial evaluating the safety and...

FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019

September 3, 2019 — Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug...

First-in-Human Telerobotic Coronary Intervention Procedures Published in EClinicalMedicine
News | Robotic Systems | September 03, 2019

September 3, 2019 — Corindus Vascular Robotics Inc. announced that EClinicalMedicine, a clinical journal published...

Merit Medical Launches PreludeSync Evo Radial Compression Device
News | Hemostasis Management | August 29, 2019

August 29, 2019 – Merit Medical Systems Inc. announced the U.S. commercial launch of the PreludeSync Evo...

FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor

August 28, 2019 — The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the...

AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices
News | Left Atrial Appendage (LAA) Occluders | August 28, 2019

August 28, 2019 — AtriCure Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance...

New Report Says Concept Medical Positioned to Disrupt Peripheral Market
News | Peripheral Artery Disease (PAD) | August 27, 2019

August 27, 2019 — Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug...

Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025
News | Stents | August 21, 2019

August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the...

FDA Approves Sapien 3, CoreValve Evolut TAVR Valves for Low-risk Patients

Left, an illustration of the beginning of deployment for a CoreValve Evolut self-expanding transcatheter aortic replacement (TAVR) valve. Right, an illustration of the final balloon expansion of an Edwards Lifesciences Sapien 3 TAVR valve. Both valves received simultaneous FDA clearance for use in low-risk surgical patients. Clearing this last hurdle now allows wide-spread use of minimally invasive TAVR in all patients who otherwise would need an open-heart surgical valve replacement. 

Feature | Heart Valve Technology | August 16, 2019 | Jeff Zagoudis, Associate Editor, and Dave Fornell, Editor

August 16, 2019 — In one coordinated move, the U.S. Food and Drug Administration (FDA) opened use of ...

Corindus Vascular Robotics to Be Acquired by Siemens Healthineers
News | Robotic Systems | August 08, 2019 | Jeff Zagoudis, Associate Editor

August 8, 2019 — Corindus Vascular Robotics announced it has entered into a definitive merger agreement to be...

Abbott Receives U.S. Approval of Next-generation MitraClip G4
Technology | Heart Valve Technology | July 17, 2019

July 17, 2019 — Abbott has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip...

Neovasc Tiara, Reducer Transcatheter Devices Featured at CSI Frankfurt 2019 Conference
News | Heart Valve Technology | July 09, 2019

July 9, 2019 — Neovasc Inc. announced that its Tiara...

Study Shows Inducing a Heart Attack Helps Valve Patients. This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates some of the tissue in the septum to allow for a larger LVOT area.

This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates (kills) some of the tissue in the cardiac septum to allow these valves to fit better and allow for an enlarged neo-LVOT for patients who otherwise could not receive this therapy. 

News | Heart Valve Technology | July 03, 2019

July 3, 2019 — A ...

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019

June 20, 2019 – VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between...

Orchestra BioMed Partnering With Terumo Corp. for Development, Commercialization of Virtue Sirolimus-eluting Balloon
News | Drug-Eluting Balloons | June 13, 2019

June 13, 2019 — Orchestra BioMed Inc. announced it has formed a global strategic partnership with Terumo Corp. for...

Overlay Init